Macrophage Imaging in Central Nervous System and in Carotid Atherosclerotic Plaque Using Ultrasmall Superparamagnetic Iron Oxide in Magnetic Resonance Imaging

The long blood circulating time and the progressive macrophage uptake in inflammatory tissues of ultrasmall superparamagnetic iron oxide (USPIO) particles are 2 properties of major importance for magnetic resonance imaging (MRI) pathologic tissue characterization. This article reviews the proof of principle of applications such as imaging of carotid atherosclerotic plaque, stroke, brain tumor characterization, or multiple sclerosis. In the human carotid artery, USPIO accumulation in activated macrophages induced a focal drop in signal intensity compared with preinfusion MRI. The USPIO signal alterations observed in ischemic areas of stroke patients is probably related to the visualization of inflammatory macrophage recruitment into human brain infarction since animal experiments in such models demonstrated the internalization of USPIO into the macrophages localized in these areas. In brain tumors, USPIO particles which do not pass the ruptured blood-brain barrier at early times postinjection can be used to assess tumoral microvascular heterogeneity. Twenty-four hours after injection, when the cellular phase of USPIO takes place, the USPIO tumoral contrast enhancement was higher in high-grade than in low-grade tumors. Several experimental studies and a pilot multiple sclerosis clinical trial in 10 patients have shown that USPIO contrast agents can reveal the presence of inflammatory multiple sclerosis lesions. The enhancement with USPIO does not completely overlap with the gadolinium chelate enhancement. While the proof of concept that USPIO can visualize macrophage infiltrations has been confirmed in animals and patients in several applications (carotid atherosclerotic lesions, stroke, brain tumors and multiple sclerosis), larger prospective clinical studies are needed to demonstrate the clinical benefit of using USPIO as an MRI in vivo surrogate marker for brain inflammatory diseases.

[1]  R Weissleder,et al.  Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[2]  Hong Wang,et al.  Investigation of Mechanisms Influencing the Accumulation of Ultrasmall Superparamagnetic Iron Oxide Particles in Lymph Nodes , 1995, Investigative radiology.

[3]  J A Frank,et al.  Frequency dependence of MR relaxation times II. Iron oxides , 1993, Journal of magnetic resonance imaging : JMRI.

[4]  C. Corot,et al.  Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. , 1996, Academic radiology.

[5]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[6]  J. Debatin,et al.  Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits , 2001, Circulation.

[7]  Wolfgang Ebert,et al.  Tissue-specific MR contrast agents. , 2003, European journal of radiology.

[8]  M. Taupitz,et al.  In Vitro Characterization of Two Different Ultrasmall Iron Oxide Particles for Magnetic Resonance Cell Tracking , 2002, Investigative radiology.

[9]  R Weissleder,et al.  Improved delineation of human brain tumors on MR images using a long‐circulating, superparamagnetic iron oxide agent , 1999, Journal of magnetic resonance imaging : JMRI.

[10]  S. Schmitz,et al.  Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. , 2000, Investigative radiology.

[11]  B. Hamm,et al.  Phase I Clinical Evaluation of Citrate-coated Monocrystalline Very Small Superparamagnetic Iron Oxide Particles as a New Contrast Medium for Magnetic Resonance Imaging , 2004, Investigative radiology.

[12]  James I. Cohen,et al.  Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. , 2002, AJNR. American journal of neuroradiology.

[13]  J C Gore,et al.  Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. , 1990, Investigative radiology.

[14]  P. Jacobs,et al.  Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. , 1995, Magnetic resonance imaging.

[15]  Bernd Hamm,et al.  Monomer-Coated Very Small Superparamagnetic Iron Oxide Particles as Contrast Medium for Magnetic Resonance Imaging: Preclinical In Vivo Characterization , 2002, Investigative radiology.

[16]  M. Heller,et al.  Characterization of Ultrasmall, Paramagnetic Magnetite Particles as Superparamagnetic Contrast Agents in MRI , 2000 .

[17]  M. Rausch,et al.  Dynamic patterns of USPIO enhancement can be observed in macrophages after ischemic brain damage , 2001, Magnetic resonance in medicine.

[18]  W. Heindel,et al.  First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: Phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. , 2002, Academic radiology.

[19]  Michael Schroeter,et al.  Inflammation and glial responses in ischemic brain lesions , 1998, Progress in Neurobiology.

[20]  J. Caillé,et al.  Assessment by MRI of brain infiltration by peripheral blood macrophages in anti-VLA-4 antibody treatment of experimental autoimmune encephalomyelitis , 2003 .

[21]  B Hamm,et al.  Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles , 2001, Journal of magnetic resonance imaging : JMRI.

[22]  G Le Duc,et al.  Use of T2‐weighted susceptibility contrast MRI for mapping the blood volume in the glioma‐bearing rat brain , 1999, Magnetic resonance in medicine.

[23]  B. V. Beers,et al.  Les oxydes de fer comme agents de contraste en IRM hépatique. , 1995 .

[24]  T. Skotland,et al.  In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. , 2002, Journal of pharmaceutical and biomedical analysis.

[25]  J. Bulte,et al.  Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION‐46L enhanced in vivo MRI: Early histopathological correlation , 1998, Journal of Neuroscience Research.

[26]  New MRI Contrast Agent for Labeling of Tumor-Associated Macrophages that Stimulate Tumor Angiogenesis , 2000 .

[27]  R. Weissleder,et al.  Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.

[28]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[29]  A. Bjørnerud,et al.  NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive‐contrast MR angiography , 2000, Journal of magnetic resonance imaging : JMRI.

[30]  M. Naghavi,et al.  Superparamagnetic Iron Oxide–Based Method for Quantifying Recruitment of Monocytes to Mouse Atherosclerotic Lesions In Vivo: Enhancement by Tissue Necrosis Factor-&agr;, Interleukin-1&bgr;, and Interferon-&ggr; , 2003, Circulation.

[31]  B Quesson,et al.  In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance , 1999, Magnetic resonance in medicine.

[32]  Y Usson,et al.  In vivo assessment of tumoral angiogenesis , 2004, Magnetic resonance in medicine.

[33]  R Weissleder,et al.  Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.

[34]  M. Rausch,et al.  MRI‐based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE , 2003, Magnetic resonance in medicine.

[35]  Urs O. Häfeli,et al.  Scientific and clinical applications of magnetic carriers , 1997 .

[36]  B. Bonnemain,et al.  Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. , 1998, Journal of drug targeting.

[37]  G. Frija,et al.  Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. , 1993, Magnetic resonance imaging.

[38]  Andreas Saleh,et al.  In vivo MRI of brain in ̄ ammation in human ischaemic stroke , 2004 .

[39]  C Delalande,et al.  Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. , 1999, AJNR. American journal of neuroradiology.

[40]  A. Roch,et al.  Transverse relaxivity of particulate MRI contrast media: From theories to experiments , 1991, Magnetic resonance in medicine.

[41]  Isabelle Raynal,et al.  Macrophage Endocytosis of Superparamagnetic Iron Oxide Nanoparticles: Mechanisms and Comparison of Ferumoxides and Ferumoxtran-10 , 2004, Investigative radiology.